# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Edward W. Brooke (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML014-SYN-TD
- Date: 2003-05-12
- Fictional facility: St. Posthumous Health Center
- Fictional author: Howard Bellamy, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month follow-up on tamoxifen; germline result. **S**

## History of present illness

Mr. Brooke returns three months after his last visit, about six and a half months into tamoxifen. He has missed no doses; his pill organizer is empty on the right days. Hot flashes are unchanged, mild, two or three times a week. Asked today about sexual side effects, which were not covered at the last visit, he says his libido has been lower since starting tamoxifen; erections are adequate, and he is not troubled enough to want treatment. He has had no leg swelling or pain, chest pain, breathlessness, or change in vision, and no new lump or swelling on the chest wall or in either armpit. He met the genetic counselor four weeks ago: the multigene panel found no pathogenic variant in BRCA2, BRCA1, PALB2, CHEK2, ATM, or the other genes tested, and he was given a letter to share with his relatives. He takes vitamin D daily and walks most days. **S**

| Element | Detail |
|---|---|
| Tamoxifen | About six and a half months; no missed doses |
| Side effects | Mild hot flashes; lower libido, not bothersome; no clot symptoms |
| Genetics | No pathogenic germline variant; family letter given |
| Recurrence symptoms | None |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fatigue or weight loss |
| Endocrine | Positive | Mild hot flashes |
| Genitourinary | Positive | Lower libido; erections adequate; no urinary symptoms |
| Cardiovascular | Negative | No chest pain or leg swelling or pain |
| Eyes | Negative | No change in vision |
| Psychiatric | Negative | Mood good; PHQ-2 score 1 |

6 systems reviewed. **S**

## Current medications

- Tamoxifen 20 mg oral tablet, one tablet by mouth once daily (adjuvant endocrine therapy, planned for at least five years) **S**
- Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/74 mmHg; pulse 66 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 82.2 kg; BMI 24.5 kg/m². All vital signs are synthetic.

25-hydroxyvitamin D: 36 ng/mL; PHQ-2: 1. All results are synthetic.

## Change since baseline

- 25-hydroxyvitamin D: 24 ng/mL (low) at baseline, 36 ng/mL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Chest wall | Mastectomy scars healed on both sides; no nodule or skin change |
| Lymph nodes | No axillary, supraclavicular, or cervical nodes |
| Extremities | Arm circumferences equal; no calf swelling or tenderness |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Right breast cancer, stage IIA, no evidence of recurrence** (C50.121). No symptoms or signs of recurrence. No pathogenic germline variant, so the risk of a second breast cancer is low, there is no change to his prostate or pancreas screening, and his relatives do not need targeted testing; they can still discuss the family history with their own clinicians. **S**
   - Continue surveillance by history and examination.
   - Survivorship visit in three months.
2. **Long-term tamoxifen** (Z79.810). Good adherence. Mild hot flashes and lower libido are known effects of tamoxifen in men; neither needs treatment now. Vitamin D is now 36 ng/mL. **S**
   - Continue tamoxifen 20 mg daily.
   - If libido or erections become a problem, discuss options with Dr. Cho rather than stopping tamoxifen.
   - Continue cholecalciferol 1000 units daily.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Cancer-related history and examination of both sides of the chest wall and both axillae | Every 3 to 6 months for 3 years | Completed today | No evidence of recurrence |
| Examination | Lymphedema assessment | Every visit after axillary surgery | Completed today | No arm swelling |
| Medication safety | Venous thromboembolism symptoms on tamoxifen | Every visit on tamoxifen | Completed today | None |
| Medication safety | Hot flashes on tamoxifen | Every visit on tamoxifen | Completed today | Mild and stable |
| Medication safety | Sexual side effects of tamoxifen (libido, erectile function) | Every visit on tamoxifen | Completed today | Lower libido; erections adequate; no treatment wanted |
| Medication safety | Sexual side effects missed at the last visit | Every visit on tamoxifen | Deferred | Not asked at the previous visit, a deviation from the protocol. Asked today: a mild fall in libido that he had not raised himself and that has not affected his adherence, so no harm resulted. The question is now on his visit checklist, because men often do not mention these effects unless asked |
| Medication safety | Adherence to tamoxifen | Every visit on tamoxifen | Completed today | No missed doses by pill organizer |
| Survey | Distress and depression screen (PHQ-2) | Every visit | Completed today | PHQ-2 score 1 |
| Laboratory | 25-hydroxyvitamin D | Three months after starting a supplement | Completed today | 36 ng/mL, up from 24 |
| Laboratory | Germline multigene panel testing | Once, for every man with breast cancer | Up to date | No pathogenic variant; result reviewed with the genetic counselor four weeks ago |
| Self-management | Genetic counseling and information for relatives | With the germline result | Completed today | Family letter given; no relative is named in the record |
| Imaging | Breast imaging (mammography) | Yearly only for a remaining breast after lumpectomy, or the other breast with a predisposing variant | Not indicated | Both breasts were removed; there is no breast tissue to image |
| Laboratory | Routine blood tests, tumor markers, and CT, bone scan, or PET | Not recommended without symptoms in stage I to III disease | Not indicated | No symptoms suggesting recurrence |

## Goal progress

- Take tamoxifen every day with side effects managed, aiming to continue for at least five years. In progress; target 2003-08-11. **S**
- Complete germline genetic testing with counseling, and give him written information for his relatives. Outcome by 2003-05-12: No pathogenic variant in a multigene panel; family letter given. **S**
- Establish bone health on hormone therapy at his age: DXA, vitamin D of 30 ng/mL or more, and weight-bearing exercise. Outcome by 2003-05-12: Femoral neck T-score -1.2; vitamin D 36 ng/mL after supplementation. **S**
- Give a written survivorship care plan with the surveillance schedule. In progress; target 2003-08-11. **S**

## Guideline basis

- Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020), American Society of Clinical Oncology
- Bedrosian I, et al. Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol 2024;42(5):584-604 (2024), American Society of Clinical Oncology and Society of Surgical Oncology
- Shapiro CL, et al. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline (2019), American Society of Clinical Oncology
- CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026), Aether Forge

## Follow-up

- Survivorship visit in three months. Medical oncology review as scheduled. **S**
- Next scheduled visit 2003-08-11: survivorship visit: cancer-related history and examination, tamoxifen review, and written survivorship care plan. **S**
